04:50 PM EST, 12/16/2024 (MT Newswires) -- Knight Therapeutics ( KHTRF ) after trade Monday said its new drug submission for Qelbree, or viloxazine extended-release capsules, has been accepted for review by Health Canada.

Qelbree is a new non-stimulant medication for treating Attention-Deficit Hyperactivity Disorder (ADHD). In December 2023, Knight Therapeutics ( KHTRF ) reached an agreement with Supernus Pharmaceuticals to exclusively commercialize Qelbree in Canada, the company said.

The drug is already available in the US for ADHD treatment in patients aged six and older. It is also being studied in several clinical trials, including one testing it with psychostimulants for children and adolescents with positive results reported in September 2023, the company added.

Knight shares closed down $0.02 to $5.18 on the Toronto Stock Exchange.